MetaVia (MTVA) Hisse Fiyat

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2016-08-05. The firm is focused on developing pharmaceuticals to treat neurodegenerative disorders. The firm is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The firm also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). The company also focused on developing capsule formulation of niclosamide for coronavirus indications.